Five Under 5: Top Oncology Videos for the Week of 9/14

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma

Larry Anderson, MD, PhD, professor of internal medicine at UT Southwestern Medical Center, discussed updated efficacy and safety findings from the phase 3 AURIGA study (NCT03901963), which evaluated daratumumab and hyaluronidase-fihj (Darzalex Faspro; subcutaneous daratumumab) in combination with lenalidomide (Revlimid) compared with lenalidomide alone as maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplant (ASCT). At 36 months, the PFS rate was 76.8% with subcutaneous daratumumab plus lenalidomide vs 55.6% with lenalidomide alone, corresponding to a 45% reduction in the risk of disease progression or death (HR, 0.55; 95% CI, 0.33-0.91; P = .0183).

Factors for Lutetium Lu 177 Vipivotide Tetraxetan Use Before Docetaxel in mCRPC

Scott T. Tagawa, MD, MS, FACP, FASCO, a professor of medicine and urology at Weill Cornell Medicine and an attending physician at NewYork-Presbyterian – Weill Cornell Medical Center, sat down with OncLive during Prostate Cancer Awareness Month to discuss factors to consider when selecting between lutetium Lu 177 vipivotide tetraxetan (Pluvicto) and docetaxel for the treatment of patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC) after prior treatment with an androgen receptor pathway inhibitor (ARPI).

Rationale for Investigating Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

Domenica Lorusso, MD, PhD, the director of Gynaecological Oncology Unit at Humanitas Hospital San Pio X, and a full professor of Obstetrics and Gynaecology at Humanitas University, explained the impetus for evaluating relacorilant plus nab-paclitaxel (Abraxane) for the treatment of patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial (NCT05257408).

Perioperative Treatment Strategies in Early-Stage NSCLC

Greg Durm, MD, an associate professor of clinical medicine in the Department of Medicine, Division of Hematology/Oncology; an associate professor of clinical otolaryngology-head & neck surgery in the Department of Otolaryngology–Head and Neck Surgery; and a full member in the Department of Experimental and Developmental Therapeutics at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, discussed clinical factors that influence his decision to utilize perioperative treatment in patients with early-stage non–small cell lung cancer (NSCLC).

Linvoseltamab in High-Risk Smoldering Myeloma

Paula Rodriguez-Otero, MD, a consultant hematologist and deputy professor at Clínica Universidad de Navarra, discussed safety and efficacy findings with linvoseltamab-gcpt (Lynozyfic) in patients with high-risk smoldering multiple myeloma.

During the 22nd Annual International Myeloma Society Meeting and Exposition, Rodriguez-Otero presented the first results from the phase 2 LINKER-SMM1 trial (NCT05932680), which showed that efficacy-evaluable patients (n = 19) achieved an overall response rate (ORR) was 100% at a median follow-up of 3.9 months. The rate of very good partial response (VGPR) or better was 73.7%, and the complete response (CR) or better rate was 36.8%. In the safety run-in portion (n = 6; median follow-up 12.7 months), 83.3% of patients achieved CR or better, suggesting that responses with linvoseltamab deepened over time.